Linked Life Data

8097759

Source:http://linkedlifedata.com/resource/pubmed/id/8097759

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1993-6-3
pubmed:abstractText
T cell responses play a critical role in host defense against viral infection. Therefore, the functional properties of HIV-1-specific human T cells induced by an experimental AIDS vaccine were analyzed in detail at the clonal level. Seronegative human volunteers were immunized with a purified recombinant form of the HIV-1 envelope glycoprotein gp160 in a phase I vaccine trial. In a subset of gp160 recipients, this vaccine was shown to elicit a virus-specific CTL response. Antibody blocking and single cell cloning experiments demonstrated that the vaccine-induced cytolytic activity was mediated by CD4+, MHC class II-restricted T cells. Because little is known about the regulation of CD4+ CTL in any system, a detailed analysis of CTL responses in vaccinees was carried out. Longitudinal and cross-sectional studies revealed that the CD4+ CTL response was regulated in a complex manner and was not clearly correlated with MHC class II genotype, Ag dose, or number of immunizations. Cloning studies were carried out to determine what fraction of the vaccine-induced T cells were cytolytic and to examine patterns of cytokine production by vaccine-induced T cells. These experiments demonstrated that, for some vaccinees, CD4+ CTL dominated the in vitro T cell response to gp160 at certain time points. The level of cytolytic activity, which was a stable property of individual clones, varied among clones over a wide and continuous range. Analysis of cytokine secretion by gp160-specific CD4+ T cell clones revealed Th0-, Th1-, and Th2-like patterns, with CD4+ CTL clones showing Th0- or T'1-like patterns. Interestingly, many Th0- and Th1-like CTL clones produced very little IL-2, a finding that may explain the complicated regulation of this response. These results illustrate the complex nature of the human T cell response to subunit vaccines consisting of purified recombinant viral proteins.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
150
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4672-86
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:8097759-AIDS Vaccines, pubmed-meshheading:8097759-CD4-Positive T-Lymphocytes, pubmed-meshheading:8097759-Clone Cells, pubmed-meshheading:8097759-Cytokines, pubmed-meshheading:8097759-Cytotoxicity, Immunologic, pubmed-meshheading:8097759-Gene Products, env, pubmed-meshheading:8097759-Gene Rearrangement, beta-Chain T-Cell Antigen Receptor, pubmed-meshheading:8097759-HIV Envelope Protein gp160, pubmed-meshheading:8097759-HIV Seropositivity, pubmed-meshheading:8097759-HIV-1, pubmed-meshheading:8097759-Humans, pubmed-meshheading:8097759-Immunity, Cellular, pubmed-meshheading:8097759-Protein Precursors, pubmed-meshheading:8097759-Receptors, Antigen, T-Cell, alpha-beta, pubmed-meshheading:8097759-T-Lymphocyte Subsets, pubmed-meshheading:8097759-T-Lymphocytes, Cytotoxic, pubmed-meshheading:8097759-Time Factors
pubmed:year
1993
pubmed:articleTitle
An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
pubmed:affiliation
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.